212 related articles for article (PubMed ID: 199761)
1. [Characteristics of alpha-toxin of Clostridium perfringens and its role in the pathogenesis of gas gangrene (author's transl)].
Murata R; Ohsaka A
Nihon Saikingaku Zasshi; 1977 Sep; 32(5):671-89. PubMed ID: 199761
[No Abstract] [Full Text] [Related]
2. The role of alpha-toxin of Clostridium perfringens in experimental gas gangrene in guinea pigs.
Kameyama S; Sato H; Murata R
Jpn J Med Sci Biol; 1972 Jun; 25(3):200. PubMed ID: 4345498
[No Abstract] [Full Text] [Related]
3. Clostridium perfringens toxins (type A, B, C, D, E).
McDonel JL
Pharmacol Ther; 1980; 10(3):617-55. PubMed ID: 6255496
[No Abstract] [Full Text] [Related]
4. Clostridium perfringens vaccines.
Titball RW
Vaccine; 2009 Nov; 27 Suppl 4():D44-7. PubMed ID: 19837285
[TBL] [Abstract][Full Text] [Related]
5. [alpha-toxin (phospholipase C) of Clostridium perfringens (author's transl)].
Ohsaka A
Tanpakushitsu Kakusan Koso; 1976 Nov; Suppl():121-44. PubMed ID: 194279
[No Abstract] [Full Text] [Related]
6. [Clostridium infections in leukemias and malignant neoplasms].
Wallner G; Misiuna P; Cygan W; Cygan Z
Pol Merkur Lekarski; 2004 Oct; 17(100):403-6. PubMed ID: 15690715
[TBL] [Abstract][Full Text] [Related]
7. Vaccines against Clostridium perfringens alpha-toxin.
Nagahama M
Curr Pharm Biotechnol; 2013; 14(10):913-7. PubMed ID: 24372250
[TBL] [Abstract][Full Text] [Related]
8. [Gas gangrene--case diagnosis].
Wojdat E; Kwiatek K; Zdrojewski H; Krupa L
Przegl Epidemiol; 2005; 59(4):859-63. PubMed ID: 16729427
[TBL] [Abstract][Full Text] [Related]
9. [Symposium II: Gas gangrene and toxins].
Ito A
Nihon Saikingaku Zasshi; 1974 Jan; 29(1):64-6. PubMed ID: 4365640
[No Abstract] [Full Text] [Related]
10. [Ultrastructural changes in skeletal muscles in experimental gas gangrene with Clostridium perfringens (author's transl)].
Kaiserling E
Zentralbl Allg Pathol; 1974; 118(2-3):182-95. PubMed ID: 4138778
[No Abstract] [Full Text] [Related]
11. [Experimental investigations in guinea pigs on the therapy of gas gangrene with ozone. A preliminary report (author's transl)].
Rotter M; Mittermayer H; Kundi M; Gruber H
Wien Klin Wochenschr; 1974 Dec; 86(24):776-8. PubMed ID: 4373940
[No Abstract] [Full Text] [Related]
12. The role of clostridial toxins in the pathogenesis of gas gangrene.
Stevens DL; Bryant AE
Clin Infect Dis; 2002 Sep; 35(Suppl 1):S93-S100. PubMed ID: 12173116
[TBL] [Abstract][Full Text] [Related]
13. [Detection of toxins of Clostridium perfringens type A in infected animals by using the ELISA test].
Nowakowska M; Bartoszcze M; Matras J
Med Dosw Mikrobiol; 1989; 41(3-4):166-9. PubMed ID: 2561810
[TBL] [Abstract][Full Text] [Related]
14. [Experimental studies on animals on the use of pyrrolidino-methyl-tetracycline and penicillin G on the prophylaxis and therapy of gas gangrene].
Klose F; Schallehn G
Arzneimittelforschung; 1966 Nov; 16(11):1543-5. PubMed ID: 4299480
[No Abstract] [Full Text] [Related]
15. Pathogenesis of Clostridium perfringens infection: mechanisms and mediators of shock.
Stevens DL; Bryant AE
Clin Infect Dis; 1997 Sep; 25 Suppl 2():S160-4. PubMed ID: 9310664
[No Abstract] [Full Text] [Related]
16. Development of monoclonal antibodies suitable for use in antigen quantification potency tests for clostridial veterinary vaccines.
Hauer PJ; Clough NE
Dev Biol Stand; 1999; 101():85-94. PubMed ID: 10566780
[TBL] [Abstract][Full Text] [Related]
17. Effects of Clostridium perfringens alpha-toxin (PLC) and perfringolysin O (PFO) on cytotoxicity to macrophages, on escape from the phagosomes of macrophages, and on persistence of C. perfringens in host tissues.
O'Brien DK; Melville SB
Infect Immun; 2004 Sep; 72(9):5204-15. PubMed ID: 15322015
[TBL] [Abstract][Full Text] [Related]
18. Enteritis necroticans (Pigbel) an unrecognised preventable disease?
Murrell TG
Chin Med J (Engl); 1982 Nov; 95(11):843-8. PubMed ID: 6299659
[No Abstract] [Full Text] [Related]
19. [Diseases in man and animal caused by Clostridium perfringens and their relations].
Köhler B
Z Gesamte Hyg; 1973 Mar; 19(3):228-34. PubMed ID: 4353612
[No Abstract] [Full Text] [Related]
20. [Factors modulating production of antibodies against Clostridium perfringens in mammals].
Shemanova GF; Sergeeva TI; Panteleev EI; Vlasova EV; Dmitrieva LN
Biull Eksp Biol Med; 1981 Sep; 92(9):322-5. PubMed ID: 6271303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
